Madrigal raises $500M for NASH drug launch, discloses cyberattack

Madri­gal Phar­ma­ceu­ti­cals ex­pects to raise $500 mil­lion from a stock and war­rants sale, which it plans to use to pre­pare for the launch of resme­tirom if it’s ap­proved next year for an ad­vanced liv­er dis­ease called non­al­co­holic steato­hep­ati­tis, or NASH.

The drug could be­come the first com­mer­cial­ly avail­able treat­ment for NASH.

Aside from the launch, the mon­ey could be used for R&D work, clin­i­cal tri­al and man­u­fac­tur­ing costs, and no­tably “po­ten­tial ac­qui­si­tions or li­cens­ing of new tech­nolo­gies,” Madri­gal said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.